143 related articles for article (PubMed ID: 11707975)
41. Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.
Yamada Y; Ohtsu A; Boku N; Miyata Y; Shimada Y; Doi T; Muro K; Muto M; Hamaguchi T; Mera K; Yano T; Tanigawara Y; Shirao K
Jpn J Clin Oncol; 2006 Apr; 36(4):218-23. PubMed ID: 16684860
[TBL] [Abstract][Full Text] [Related]
42. [Combination chemotherapy with FP versus FEP in patients with advanced gastric cancer. Research group of gastric cancer chemotherapy].
Shinoda M; Morise K; Kusugami K; Iwase H; Ina K; Kaneko H; Horiuchi Y; Kuroiwa A; Suga S; Oka Y
Gan To Kagaku Ryoho; 1995 Mar; 22(4):515-20. PubMed ID: 7887643
[TBL] [Abstract][Full Text] [Related]
43. [A study of combined chemotherapy with MMC, ADM, CDDP, etoposide (VP-16), 5'DFUR (MAC-VD therapy) in advanced cancer and local relapse of the stomach].
Yasutake K; Imamura Y; Yoshimura Y; Oya M; Matsushita K; Tokisue M; Ohno S; Masuda T
Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):397-401. PubMed ID: 2138004
[TBL] [Abstract][Full Text] [Related]
44. [Effects of combination chemotherapy using 5-FU, leucovorin, and CDDP (FLP therapy) for noncurative resected or recurrent stomach cancer in outpatients].
Okugawa T; Onodera S; Rino Y; Okada K; Kobayashi O; Sairenji M; Motohashi H
Gan To Kagaku Ryoho; 1994 Jul; 21(8):1193-7. PubMed ID: 8031161
[TBL] [Abstract][Full Text] [Related]
45. FLEP chemotherapy for alpha-fetoprotein-producing gastric cancer.
Kochi M; Fujii M; Kaiga T; Takahashi T; Morishita Y; Kobayashi M; Kasakura Y; Takayama T
Oncology; 2004; 66(6):445-9. PubMed ID: 15452373
[TBL] [Abstract][Full Text] [Related]
46. A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer.
Kim SG; Oh SY; Kwon HC; Lee S; Kim JH; Kim SH; Kim HJ
Jpn J Clin Oncol; 2007 Oct; 37(10):744-9. PubMed ID: 17923456
[TBL] [Abstract][Full Text] [Related]
47. A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer.
Lee JJ; Kim SY; Chung HC; Lee KH; Song HS; Kang WK; Hong YS; Choi IS; Lee YY; Woo IS; Choi JH
Cancer Chemother Pharmacol; 2009 May; 63(6):1083-90. PubMed ID: 18813927
[TBL] [Abstract][Full Text] [Related]
48. A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer.
Luo HY; Xu RH; Zhang L; Li YH; Shi YX; Lin TY; Han B; Wang F; Qiu MZ; He YJ; Guan ZZ
Chemotherapy; 2008; 54(3):228-35. PubMed ID: 18560231
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
50. A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer.
Im CK; Jeung HC; Rha SY; Yoo NC; Noh SH; Roh JK; Chung HC
Cancer Chemother Pharmacol; 2008 Feb; 61(2):315-21. PubMed ID: 18026677
[TBL] [Abstract][Full Text] [Related]
51. [Biweekly low-dose cisplatin and 5-fluorouracil combination chemotherapy for advanced gastrointestinal carcinoma].
Kamata T; Morita A; Nakamoto A; Onishi I; Takeda T; Koyasaki N; Kanno M
Gan To Kagaku Ryoho; 2000 Jun; 27(6):859-64. PubMed ID: 10897212
[TBL] [Abstract][Full Text] [Related]
52. Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer.
Cao W; Yang W; Lou G; Jiang J; Geng M; Xi W; Li H; Ma T; Jin Y
Anticancer Drugs; 2009 Apr; 20(4):287-93. PubMed ID: 19177020
[TBL] [Abstract][Full Text] [Related]
53. A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 trial.
Hamaguchi T; Shirao K; Yamamichi N; Hyodo I; Koizumi W; Seki S; Imamura T; Honma H; Ohtsu A; Boku N; Mukai T; Yamamoto S; Fukuda H; Yoshida S;
Jpn J Clin Oncol; 2008 Jun; 38(6):432-7. PubMed ID: 18515821
[TBL] [Abstract][Full Text] [Related]
54. [A cooperative study on concomitant with low-dose divided administration of cisplatin (CDDP) and sustained drip infusion of 5-fluorouracil (5-FU) for unresectable advanced gastric cancer. Osaka Cisplatin Gastric Cancer Study Group].
Narahara H; Otani T; Iwanaga T; Okajima K; Katsu K; Sowa M; Kobayashi K; Yasutomi M; Okuno M; Takami M; Ishida T; Yasutake K; Yamamoto H; Taguchi T
Gan To Kagaku Ryoho; 1998 Jun; 25(7):1021-6. PubMed ID: 9644317
[TBL] [Abstract][Full Text] [Related]
55. [A randomized controlled trial with methotrexate (MTX), 5-fluorouracil (5-FU) and pirarubicin (THP) vs 5-FU alone in advanced or recurrent gastric carcinoma. Tokai Hokuriku THP Study Group].
Yamamura Y; Miyazaki I; Ogawa M; Yonemura Y; Tanemura H; Kito T; Hamajima N; Saji S; Kosaka T
Gan To Kagaku Ryoho; 1998 Aug; 25(10):1543-8. PubMed ID: 9725047
[TBL] [Abstract][Full Text] [Related]
56. [Intraperitoneal administration of cis-platin with arterial infusion chemotherapy of advanced and recurrent gastric cancer].
Sato M; Terashima M; Takagane A; Yokkaichi H; Niitsu Y; Saito K
Gan To Kagaku Ryoho; 1991 Aug; 18(11):2042-6. PubMed ID: 1908668
[TBL] [Abstract][Full Text] [Related]
57. [A controlled study of AO-90, a methionine-free intravenous amino acid solution, in combination with 5-fluorouracil and mitomycin C in advanced gastric cancer patients (surgery group evaluation)].
Taguchi T; Kosaki G; Onodera T; Endo M; Nakagawara G; Sano K; Kaibara N; Kakegawa T; Nakano S; Kurihara M
Gan To Kagaku Ryoho; 1995 May; 22(6):753-64. PubMed ID: 7755383
[TBL] [Abstract][Full Text] [Related]
58. [The clinical effect of low-dose FP (5-FU + low-dose CDDP) in patients with far advanced gastric cancer, and their quality of life].
Murakami S; Yoshida K; Kin R; Nishimoto N; Kagawa Y; Yano Y; Nishiyama M; Hirai T; Toge T
Gan To Kagaku Ryoho; 2000 Jun; 27(6):853-8. PubMed ID: 10897211
[TBL] [Abstract][Full Text] [Related]
59. [Clinical experience of intermittent administration of 5-FU and CDDP to patients with advanced and recurrent gastric cancer].
Sekikawa K; Anzai K; Ishihata R; Yamaki T; Ohki S; Kimijima I; Takenoshita S
Gan To Kagaku Ryoho; 2001 Jun; 28(6):825-8. PubMed ID: 11432352
[TBL] [Abstract][Full Text] [Related]
60. [Significance of neoadjuvant chemotherapy for gastric cancer].
Fujii M; Kochi M; Mochizuki F
Gan To Kagaku Ryoho; 2000 Nov; 27(13):2028-32. PubMed ID: 11103233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
